-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate

Benzinga·07/23/2026 20:09:02
Listen to the news
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.28) by 32.14 percent. This is a 58.33 percent decrease over losses of $(0.12) per share from the same period last year.